Johnson & Johnson Reports 2016 Third-Quarter Results:

Dienstag, 18.10.2016 12:45 von

PR Newswire

NEW BRUNSWICK, N.J., Oct. 18, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.8 billion for the third quarter of 2016, an increase of 4.2% as compared to the third quarter of 2015. Operational sales results increased 4.3% and the negative impact of currency was 0.1%. Domestic sales increased 6.7%. International sales increased 1.5%, reflecting operational growth of 1.7% and a negative currency impact of 0.2%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 5.9%, domestic sales increased 7.3% and international sales increased 4.2%.* Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points.  

Net earnings and diluted earnings per share for the third quarter of 2016 were $4.3 billion and $1.53, respectively. Third quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.2 billion. Third quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.4 billion and a charge for after-tax special items of approximately $0.4 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.7 billion and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015.* On an operational basis, adjusted diluted earnings per share also increased 12.8%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion," said Alex Gorsky, Chairman and Chief Executive Officer. "Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care."

The Company maintained its sales guidance for the full-year 2016 of $71.5 billion to $72.2 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2016 to $6.68 - $6.73 per share.*

Worldwide Consumer sales of $3.3 billion for the third quarter 2016 represented a decrease of 1.6% versus the prior year, consisting of an operational increase of 0.1% and a negative impact from currency of 1.7%. Domestic sales increased 1.1%; international sales decreased 3.3%, which reflected an operational decrease of 0.6% and a negative currency impact of 2.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 0.4%, domestic sales decreased 1.5% and international sales increased 0.3%*. Operations in Venezuela negatively impacted worldwide Consumer operational sales growth by 110 basis points and international sales growth by 180 basis points.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by lower trade inventory levels, primarily in the U.S. Positive contributors to Consumer operational sales results included LISTERINE® oral care products; AVEENO® skin care products and digestive health products and international smoking aids in over-the-counter products.

Worldwide Pharmaceutical sales of $8.4 billion for the third quarter 2016 represented an increase of 9.2% versus the prior year with an operational increase of 9.0% and a positive impact from currency of 0.2%. Domestic sales increased 11.8%; international sales increased 5.4%, which reflected an operational increase of 5.0% and a positive currency impact of 0.4%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 10.7%, domestic sales increased 13.0% and international sales increased 7.0%.* 

Worldwide operational results, excluding the net impact of acquisitions, divestitures and hepatitis C sales, were driven by new products and the strength of core products. Strong growth in new products include IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; DARZALEX® (daratumumab), for the treatment of patients with multiple myeloma; and XARELTO® (rivaroxaban), an oral anticoagulant.

Additional contributors to operational sales growth included STELARA® (ustekinumab), REMICADE® (infliximab) and SIMPONI®/SIMPONI ARIA® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; and INVEGA® SUSTENNA®/XEPLION®/TRINZA® (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

During the quarter, the U.S. Food and Drug Administration (FDA) approved INVOKAMET® XR (canagliflozin/metformin HCl extended-release) for first-line treatment of adults with type 2 diabetes, and STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn's disease. The Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of STELARA® for the treatment of adults with moderately to severely active Crohn's disease.

Additionally, regulatory applications for approval were submitted to the FDA and European Medicines Agency (EMA) for DARZALEX® in combination with standard-of-care regimens for patients with multiple myeloma who have received at least one prior therapy.  DARZALEX® also received Breakthrough Therapy Designation from the FDA for this pending indication. The FDA also granted Breakthrough Therapy Designation to esketamine for major depressive disorder with imminent risk for suicide.  Regulatory applications for approval were also submitted to the FDA for sirukumab in rheumatoid arthritis, and to EMA for a darunavir-based single tablet regimen for the treatment of HIV-1. 

Worldwide Medical Devices sales of $6.2 billion for the third quarter 2016 represented an increase of 1.1% versus the prior year consisting of an operational increase of 0.7% and a positive currency impact of 0.4%. Domestic sales increased 1.4%; international sales increased 0.7%, which reflected an operational decline of 0.2% and a positive currency impact of 0.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 3.1%, domestic sales increased 2.3% and international sales increased 3.9%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business; endocutters and energy in the Advanced Surgery business; ACUVUE® contact lenses in the Vision Care business; and joint reconstruction and trauma products in the Orthopaedics business.

During the quarter, a definitive agreement was announced to acquire Abbott Medical Optics, a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash.  Acclarent announced the U.S. launch of ACCLARENT AERA, the first balloon dilation intervention approved by the FDA for Eustachian Tube Dysfunction.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the company's website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; market conditions and the possibility that the on-going share repurchase program may be delayed, suspended or discontinued; the impact of business combinations and divestitures; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

 

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

THIRD QUARTER


NINE MONTHS






Percent Change






Percent Change


2016


2015


Total


Operations


Currency


2016


2015


Total


Operations


Currency

Sales to customers by




















segment of business








































Consumer




















    U.S.

$   1,291


1,277


1.1

%

1.1


-


$   4,033


3,991


1.1

%

1.1


-

    International

1,970


2,037


(3.3)


(0.6)


(2.7)


5,842


6,196


(5.7)


0.1


(5.8)


3,261


3,314


(1.6)


0.1


(1.7)


9,875


10,187


(3.1)


0.4


(3.5)





















Pharmaceutical




















    U.S.

5,042


4,509


11.8


11.8


-


15,123


13,423


12.7


12.7


-

    International

3,358


3,185


5.4


5.0


0.4


10,109


9,943


1.7


4.2


(2.5)


8,400


7,694


9.2


9.0


0.2


25,232


23,366


8.0


9.1


(1.1)





















Medical Devices




















    U.S.

3,048


3,005


1.4


1.4


-


9,118


8,980


1.5


1.5


-

    International

3,111


3,089


0.7


(0.2)


0.9


9,559


9,730


(1.8)


0.5


(2.3)


6,159


6,094


1.1


0.7


0.4


18,677


18,710


(0.2)


1.0


(1.2)





















U.S.

9,381


8,791


6.7


6.7


-


28,274


26,394


7.1


7.1


-

International

8,439


8,311


1.5


1.7


(0.2)


25,510


25,869


(1.4)


1.8


(3.2)

Worldwide

$ 17,820


17,102


4.2

%

4.3


(0.1)


$ 53,784


52,263


2.9

%

4.5


(1.6)





















 

 

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

THIRD QUARTER


NINE MONTHS






Percent Change






Percent Change


2016


2015


Total


Operations


Currency


2016


2015


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$   9,381


8,791


6.7

%

6.7


-


$ 28,274


26,394


7.1

%

7.1


-





















Europe

3,832


3,802


0.8


3.2


(2.4)


11,769


11,993


(1.9)


0.5


(2.4)

Western Hemisphere excluding U.S.

1,396


1,463


(4.6)


(1.3)


(3.3)


4,269


4,603


(7.3)


4.4


(11.7)

Asia-Pacific, Africa

3,211


3,046


5.4


1.4


4.0


9,472


9,273


2.1


2.1


0.0

International

8,439


8,311


1.5


1.7


(0.2)


25,510


25,869


(1.4)


1.8


(3.2)





















Worldwide

$ 17,820


17,102


4.2

%

4.3


(0.1)


$ 53,784


52,263


2.9

%

4.5


(1.6)





















 

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

THIRD QUARTER












2016


2015


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$         17,820


100.0


$         17,102


100.0


4.2

Cost of products sold

5,486


30.8


5,224


30.5


5.0

Selling, marketing and administrative expenses

4,772


26.8


5,081


29.7


(6.1)

Research and development expense

2,178


12.2


2,154


12.6


1.1

In-process research and development

-


-


10


0.1



Interest (income) expense, net

95


0.5


91


0.5



Other (income) expense, net

(54)


(0.2)


420


2.5



Restructuring

62


0.3


-


-



Earnings before provision for taxes on income

5,281


29.6


4,122


24.1


28.1

Provision for taxes on income

1,009


5.6


764


4.5


32.1

Net earnings

$           4,272


24.0


$           3,358


19.6


27.2











Net earnings per share (Diluted)

$             1.53




$             1.20




27.5











Average shares outstanding (Diluted)

2,785.4




2,807.2















Effective tax rate

19.1

%



18.5

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$           5,831


32.7


$           5,212


30.5


11.9

Net earnings

$           4,683


26.3


$           4,172


24.4


12.2

Net earnings per share (Diluted)

$             1.68




$             1.49




12.8

Effective tax rate

19.7

%



20.0

%














(1) See Reconciliation of Non-GAAP Financial Measures.
















 

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

NINE MONTHS












2016


2015


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$         53,784


100.0


$         52,263


100.0


2.9

Cost of products sold

16,151


30.0


15,863


30.4


1.8

Selling, marketing and administrative expenses

14,636


27.2


15,312


29.3


(4.4)

Research and development expense

6,455


12.0


6,182


11.8


4.4

In-process research and development

29


0.1


10


0.0



Interest (income) expense, net

274


0.5


317


0.6



Other (income) expense, net

464


0.9


(859)


(1.6)



Restructuring

296


0.5


-


-



Earnings before provision for taxes on income

15,479


28.8


15,438


29.5


0.3

Provision for taxes on income

2,753


5.1


3,244


6.2


(15.1)

Net earnings

$         12,726


23.7


$         12,194


23.3


4.4











Net earnings per share (Diluted)

$             4.55




$             4.33




5.1











Average shares outstanding (Diluted)

2,796.6




2,817.1















Effective tax rate

17.8

%



21.0

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$         17,656


32.8


$         17,090


32.7


3.3

Net earnings

$         14,403


26.8


$         13,402


25.6


7.5

Net earnings per share (Diluted)

$             5.15




$             4.76




8.2

Effective tax rate

18.4

%



21.6

%














(1) See Reconciliation of Non-GAAP Financial Measures.







 

 

Johnson & Johnson and Subsidiaries














Reconciliation of Non-GAAP Financial Measures





























Third Quarter


% Incr. /



Nine Months YTD


% Incr. /


(Dollars in Millions Except Per Share Data)

2016


2015


(Decr.)



2016


2015


(Decr.)
















Earnings before provision for taxes on income - as reported

$ 5,281


4,122


28.1

%


$ 15,479


15,438


0.3

%















Intangible asset amortization expense

319


639





927


1,269


















Restructuring/Other (1)

109


-





387


-


















Litigation expense, net

55


409





721


141


















DePuy ASR Hip program

-


-





-


148


















In-process research and development

-


10





29


10


















Other

67


32





113


84


















Earnings before provision for taxes on income - as adjusted

$ 5,831


5,212


11.9

%


$ 17,656


17,090


3.3

%















Net Earnings - as reported

$ 4,272


3,358


27.2

%


$ 12,726


12,194


4.4

%















Intangible asset amortization expense

236


437





679


893


















Restructuring/Other

76


-





293


-


















Litigation expense, net

46


348





595


118


















DePuy ASRHip program

-


-





-


130


















In-process research and development

-


6





23


6


















Other

53


23





87


61


















Net Earnings - as adjusted 

$ 4,683


4,172


12.2

%


$ 14,403


13,402


7.5

%















Diluted Net Earnings per share - as reported

$   1.53


1.20


27.5

%


$     4.55


4.33


5.1

%















Intangible asset amortization expense

0.08


0.16





0.24


0.32


















Restructuring/Other

0.03


-





0.11


-


















Litigation expense, net

0.02


0.12





0.21


0.04


















DePuy ASR Hip program

-


-





-


0.05


















In-process research and development

-


-





0.01


-


















Other

0.02


0.01





0.03


0.02


















Diluted Net Earnings per share - as adjusted 

$   1.68


1.49


12.8

%


$     5.15


4.76


8.2

%















Operational Diluted Net Earnings per share - as adjusted at 2014 foreign currency exchange rates



1.63







5.22


















Impact of currency at 2015 foreign currency exchange rates

$       -


(0.14)





$     0.04


(0.46)


















Operational Diluted Net Earnings per share - as adjusted at 2015 foreign currency exchange rates

$   1.68


1.49


12.8

%


$     5.19


4.76


9.0

%















(1) Includes $3M recorded in cost of products sold and $44M recorded in other (income) expense for the third quarter. 

    Includes $27M recorded in cost of products sold and $64M recorded in other (income) expense for nine months YTD.

 

 

Johnson & Johnson and Subsidiaries









Reconciliation of Non-GAAP Financial Measure


















Operational Sales Growth Excluding Acquisitions, Divestitures, and Hepatitis C Sales(1)

 THIRD QUARTER 2016 ACTUAL vs. 2015 ACTUAL 


 Segments 












 Consumer 


 Pharmaceutical 


 Medical Devices 


 Total 



Operational %(2)

 WW As Reported: 


0.1%


9.0%


0.7%


4.3%

 U.S. 


1.1%


11.8%


1.4%


6.7%

 International 


(0.6)%


5.0%


(0.2)%


1.7%










Wound Care/Other









SPLENDA®


2.1






0.4

 U.S. 


4.0






0.6

 International 


1.0






0.2










Cardiovascular









Cordis






2.3


0.9

 U.S. 






1.1


0.4

 International 






3.7


1.4










Skin Care


(2.3)







Vogue


(5.8)






(0.4)

 U.S. 


0.0






(0.8)

 International 








0.0










Other Neuroscience









Controlled Substance Raw Material and API Business




0.7




0.3

 U.S. 




0.9




0.4

 International 




0.4




0.1










All Other Acquisitions and Divestitures


(0.3)


0.0


0.1


0.0

 U.S. 


(0.8)


0.0


(0.2)


(0.2)

 International 


(0.1)


0.0


0.4


0.2










WW Ops excluding Acquisitions and Divestitures


(0.4)%


9.7%


3.1%


5.5%

 U.S. 


(1.5)%


12.7%


2.3%


7.1%

 International 


0.3%


5.4%


3.9%


3.6%










Hepatitis C




1.0




0.4

 U.S. 




0.3




0.2

 International 




1.6




0.6










WW Ops excluding Hepatitis C only




10.0%




4.7%

 U.S. 




12.1%




6.9%

 International 




6.6%




2.3%










WW Ops excluding Acquisitions, Divestitures and Hepatitis C


(0.4)%


10.7%


3.1%


5.9%

 U.S. 


(1.5)%


13.0%


2.3%


7.3%

 International 


0.3%


7.0%


3.9%


4.2%










(1) Hepatitis C products include OLYSIO®/SOVRIAD®and INCIVO®




(2) Operational growth excludes the effect of translational currency




 

 

Johnson & Johnson and Subsidiaries









Reconciliation of Non-GAAP Financial Measure


















Operational Sales Growth Excluding Acquisitions, Divestitures, and Hepatitis C Sales(1)

 NINE MONTHS 2016 ACTUAL vs. 2015 ACTUAL 


 Segments 












 Consumer 


 Pharmaceutical 


 Medical Devices 


 Total 



Operational %(2)

 WW As Reported: 


0.4%


9.1%


1.0%


4.5%

 U.S. 


1.1%


12.7%


1.5%


7.1%

 International 


0.1%


4.2%


0.5%


1.8%










Wound Care/Other









SPLENDA®


2.2






0.4

 U.S. 


4.3






0.7

 International 


0.9






0.2










Cardiovascular









Cordis






2.4


0.9

 U.S. 






1.1


0.4

 International 






3.5


1.3










Skin Care


(0.7)







Vogue


(1.9)






(0.1)

 U.S. 


0.0






(0.3)

 International 








0.0










All Other Acquisitions and Divestitures


(0.1)


0.4


0.0


0.1

 U.S. 


(0.3)


0.7


(0.1)


0.2

 International 


0.0


0.0


0.1


0.1










WW Ops excluding Acquisitions and Divestitures


1.8%


9.5%


3.4%


5.8%

 U.S. 


3.2%


13.4%


2.5%


8.1%

 International 


1.0%


4.2%


4.1%


3.4%










Hepatitis C




2.4




1.1

 U.S. 




1.1




0.6

 International 




4.2




1.6










WW Ops excluding Hepatitis C only




11.5%




5.6%

 U.S. 




13.8%




7.7%

 International 




8.4%




3.4%










WW Ops excluding Acquisitions, Divestitures, and Hepatitis C


1.8%


11.9%


3.4%


6.9%

 U.S. 


3.2%


14.5%


2.5%


8.7%

 International 


1.0%


8.4%


4.1%


5.0%










(1) Hepatitis C products include OLYSIO®/SOVRIAD®and INCIVO®





(2) Operational growth excludes the effect of translational currency




 

 


 

REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2)
















BABY CARE
















US


$           96


103

-6.8%

-6.8%

-



$           293


$         318

-7.9%

-7.9%

-

Intl


370


403

-8.2%

-5.3%

-2.9%



1,124


1,242

-9.5%

-2.5%

-7.0%

WW


466


506

-7.9%

-5.6%

-2.3%



1,417


1,560

-9.2%

-3.6%

-5.6%

ORAL CARE
















US


156


154

1.3%

1.3%

-



485


459

5.7%

5.7%

-

Intl


227


224

1.3%

3.1%

-1.8%



686


713

-3.8%

1.8%

-5.6%

WW


383


378

1.3%

2.3%

-1.0%



1,171


1,172

-0.1%

3.3%

-3.4%

OTC
















US


380


383

-0.8%

-0.8%

-



1,230


1,154

6.6%

6.6%

-

Intl


584


580

0.7%

3.5%

-2.8%



1,761


1,776

-0.8%

4.2%

-5.0%

WW


964


963

0.1%

1.8%

-1.7%



2,991


2,930

2.1%

5.1%

-3.0%

SKIN CARE
















US


517


435

18.9%

18.9%

-



1,560


1,418

10.0%

10.0%

-

Intl


438


428

2.3%

5.3%

-3.0%



1,210


1,242

-2.6%

2.7%

-5.3%

WW


955


863

10.7%

12.2%

-1.5%



2,770


2,660

4.1%

6.6%

-2.5%

WOMEN'S HEALTH
















US


3


6

-50.0%

-50.0%

-



16


19

-15.8%

-15.8%

-

Intl


266


304

-12.5%

-9.1%

-3.4%



787


898

-12.4%

-5.1%

-7.3%

WW


269


310

-13.2%

-9.9%

-3.3%



803


917

-12.4%

-5.3%

-7.1%

WOUND CARE / OTHER
















US


139


196

-29.1%

-29.1%

-



449


623

-27.9%

-27.9%

-

Intl


85


98

-13.3%

-13.2%

-0.1%



274


325

-15.7%

-12.0%

-3.7%

WW


224


294

-23.8%

-23.8%

0.0%



723


948

-23.7%

-22.4%

-1.3%

















TOTAL CONSUMER
















US


1,291


1,277

1.1%

1.1%

-



4,033


3,991

1.1%

1.1%

-

Intl


1,970


2,037

-3.3%

-0.6%

-2.7%



5,842


6,196

-5.7%

0.1%

-5.8%

WW


$      3,261


3,314

-1.6%

0.1%

-1.7%



$        9,875


10,187

-3.1%

0.4%

-3.5%


















































REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2)
















IMMUNOLOGY
















US


$      2,294


1,910

20.1%

20.1%

-



$        6,689


5,541

20.7%

20.7%

-

Intl


790


704

12.2%

11.6%

0.6%



2,343


2,090

12.1%

15.7%

-3.6%

WW


3,084


2,614

18.0%

17.8%

0.2%



9,032


7,631

18.4%

19.4%

-1.0%

REMICADE
















US 


1,222


1,117

9.4%

9.4%

-



3,669


3,260

12.5%

12.5%

-

US Exports (3)


255


180

41.7%

41.7%

-



673


602

11.8%

11.8%

-

Intl


306


316

-3.2%

-2.9%

-0.3%



1,000


1,019

-1.9%

3.4%

-5.3%

WW


1,783


1,613

10.5%

10.6%

-0.1%



5,342


4,881

9.4%

10.5%

-1.1%

SIMPONI / SIMPONI ARIA
















US


256


199

28.6%

28.6%

-



716


526

36.1%

36.1%

-

Intl


225


181

24.3%

20.6%

3.7%



603


462

30.5%

31.3%

-0.8%

WW


481


380

26.6%

24.8%

1.8%



1,319


988

33.5%

33.9%

-0.4%

STELARA
















US


561


414

35.5%

35.5%

-



1,631


1,153

41.5%

41.5%

-

Intl


253


199

27.1%

27.8%

-0.7%



722


579

24.7%

27.2%

-2.5%

WW


814


613

32.8%

33.0%

-0.2%



2,353


1,732

35.9%

36.7%

-0.8%

OTHER IMMUNOLOGY
















US


-


-

-

-

-



-


-

-

-

-

Intl


6


8

-25.0%

-22.6%

-2.4%



18


30

-40.0%

-32.9%

-7.1%

WW


6


8

-25.0%

-22.6%

-2.4%



18


30

-40.0%

-32.9%

-7.1%

INFECTIOUS DISEASES
















US


387


379

2.1%

2.1%

-



1,107


1,172

-5.5%

-5.5%

-

Intl


455


469

-3.0%

-2.2%

-0.8%



1,340


1,683

-20.4%

-18.5%

-1.9%

WW


842


848

-0.7%

-0.3%

-0.4%



2,447


2,855

-14.3%

-13.2%

-1.1%

EDURANT
















US


13


11

18.2%

18.2%

-



38


29

31.0%

31.0%

-

Intl


136


100

36.0%

35.4%

0.6%



370


274

35.0%

35.2%

-0.2%

WW


149


111

34.2%

33.7%

0.5%



408


303

34.7%

34.9%

-0.2%

OLYSIO / SOVRIAD
















US


13


26

-50.0%

-50.0%

-



50


174

-71.3%

-71.3%

-

Intl


8


53

-84.9%

-85.7%

0.8%



46


403

-88.6%

-88.2%

-0.4%

WW


21


79

-73.4%

-73.9%

0.5%



96


577

-83.4%

-83.1%

-0.3%

PREZISTA / PREZCOBIX / REZOLSTA
















US


310


285

8.8%

8.8%

-



860


777

10.7%

10.7%

-

Intl


183


183

0.0%

2.0%

-2.0%



544


566

-3.9%

-1.1%

-2.8%

WW


493


468

5.3%

6.1%

-0.8%



1,404


1,343

4.5%

5.7%

-1.2%

OTHER INFECTIOUS DISEASES
















US


51


57

-10.5%

-10.5%

-



159


192

-17.2%

-17.2%

-

Intl


128


133

-3.8%

-3.0%

-0.8%



380


440

-13.6%

-10.6%

-3.0%

WW


179


190

-5.8%

-5.2%

-0.6%



539


632

-14.7%

-12.6%

-2.1%

















See footnotes at end of schedule






























REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

NEUROSCIENCE
















US


622


655

-5.0%

-5.0%

-



1,997


2,098

-4.8%

-4.8%

-

Intl


842


821

2.6%

0.0%

2.6%



2,618


2,560

2.3%

3.5%

-1.2%

WW


1,464


1,476

-0.8%

-2.2%

1.4%



4,615


4,658

-0.9%

-0.2%

-0.7%

CONCERTA / METHYLPHENIDATE
















US


102


89

14.6%

14.6%

-



365


317

15.1%

15.1%

-

Intl


88


89

-1.1%

-2.5%

1.4%



294


291

1.0%

4.4%

-3.4%

WW


190


178

6.7%

6.0%

0.7%



659


608

8.4%

10.0%

-1.6%

INVEGA
















US


28


82

-65.9%

-65.9%

-



70


281

-75.1%

-75.1%

-

Intl


59


57

3.5%

-1.0%

4.5%



185


179

3.4%

2.7%

0.7%

WW


87


139

-37.4%

-39.2%

1.8%



255


460

-44.6%

-44.9%

0.3%

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
















US


339


277

22.4%

22.4%

-



983


758

29.7%

29.7%

-

Intl


217


182

19.2%

18.8%

0.4%



646


548

17.9%

19.8%

-1.9%

WW


556


459

21.1%

20.9%

0.2%



1,629


1,306

24.7%

25.5%

-0.8%

RISPERDAL CONSTA
















US


94


103

-8.7%

-8.7%

-



289


306

-5.6%

-5.6%

-

Intl


128


132

-3.0%

-3.9%

0.9%



394


430

-8.4%

-7.1%

-1.3%

WW


222


235

-5.5%

-6.0%

0.5%



683


736

-7.2%

-6.4%

-0.8%

OTHER NEUROSCIENCE
















US


59


104

-43.3%

-43.3%

-



290


436

-33.5%

-33.5%

-

Intl


350


361

-3.0%

-7.3%

4.3%



1,099


1,112

-1.2%

-0.6%

-0.6%

WW


409


465

-12.0%

-15.3%

3.3%



1,389


1,548

-10.3%

-9.9%

-0.4%

ONCOLOGY
















US


622


394

57.9%

57.9%

-



1,740


1,090

59.6%

59.6%

-

Intl


895


776

15.3%

15.4%

-0.1%



2,605


2,332

11.7%

14.1%

-2.4%

WW


1,517


1,170

29.7%

29.7%

0.0%



4,345


3,422

27.0%

28.7%

-1.7%

IMBRUVICA
















US


179


98

82.7%

82.7%

-



455


253

79.8%

79.8%

-

Intl


170


86

97.7%

*

**



450


201

*

*

**

WW


349


184

89.7%

92.1%

-2.4%



905


454

99.3%

*

**

VELCADE
















US


-


-

-

-

-



-


-

-

-

-

Intl


304


329

-7.6%

-7.4%

-0.2%



950


1,012

-6.1%

-3.7%

-2.4%

WW


304


329

-7.6%

-7.4%

-0.2%



950


1,012

-6.1%

-3.7%

-2.4%

ZYTIGA
















US


282


276

2.2%

2.2%

-



840


784

7.1%

7.1%

-

Intl


300


272

10.3%

8.5%

1.8%



901


866

4.0%

5.4%

-1.4%

WW


582


548

6.2%

5.3%

0.9%



1,741


1,650

5.5%

6.3%

-0.8%

OTHER ONCOLOGY
















US


161


20

*

*

-



445


53

*

*

-

Intl


121


89

36.0%

36.6%

-0.6%



304


253

20.2%

23.0%

-2.8%

WW


282


109

*

*

**



749


306

*

*

**

CARDIOVASCULAR / METABOLISM / OTHER
















US


1,117


1,171

-4.6%

-4.6%

-



3,590


3,522

1.9%

1.9%

-

Intl


376


415

-9.4%

-7.4%

-2.0%



1,203


1,278

-5.9%

-1.5%

-4.4%

WW


1,493


1,586

-5.9%

-5.4%

-0.5%



4,793


4,800

-0.1%

1.1%

-1.2%

XARELTO
















US


529


461

14.8%

14.8%

-



1,690


1,374

23.0%

23.0%

-

Intl


-


-

-

-

-



-


-

-

-

-

WW


529


461

14.8%

14.8%

-



1,690


1,374

23.0%

23.0%

-

INVOKANA / INVOKAMET
















US


294


322

-8.7%

-8.7%

-



939


890

5.5%

5.5%

-

Intl


34


18

88.9%

94.3%

-5.4%



97


46

*

*

**

WW


328


340

-3.5%

-3.2%

-0.3%



1,036


936

10.7%

11.3%

-0.6%

PROCRIT / EPREX
















US


168


177

-5.1%

-5.1%

-



581


519

11.9%

11.9%

-

Intl


82


86

-4.7%

-4.7%

0.0%



265


289

-8.3%

-5.5%

-2.8%

WW


250


263

-4.9%

-4.9%

0.0%



846


808

4.7%

5.7%

-1.0%

OTHER
















US


126


211

-40.3%

-40.3%

-



380


739

-48.6%

-48.6%

-

Intl


260


311

-16.4%

-14.1%

-2.3%



841


943

-10.8%

-6.3%

-4.5%

WW


386


522

-26.1%

-24.7%

-1.4%



1,221


1,682

-27.4%

-24.9%

-2.5%

















TOTAL PHARMACEUTICAL
















US


5,042


4,509

11.8%

11.8%

-



15,123


13,423

12.7%

12.7%

-

Intl


3,358


3,185

5.4%

5.0%

0.4%



10,109


9,943

1.7%

4.2%

-2.5%

WW


$      8,400


7,694

9.2%

9.0%

0.2%



$      25,232


23,366

8.0%

9.1%

-1.1%

































See footnotes at end of schedule





























REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2016


2015

Reported

Operational (1)

Currency



2016


2015

Reported

Operational (1)

Currency

MEDICAL DEVICES SEGMENT (2) (4)
















CARDIOVASCULAR
















US


$         235


239

-1.7%

-1.7%

-



$           701


702

-0.1%

-0.1%

-

Intl


216


285

-24.2%

-26.8%

2.6%



663


895

-25.9%

-25.6%

-0.3%

WW


451


524

-13.9%

-15.3%

1.4%



1,364


1,597

-14.6%

-14.4%

-0.2%

DIABETES CARE
















US


191


205

-6.8%

-6.8%

-



548


631

-13.2%

-13.2%

-

Intl


236


265

-10.9%

-11.2%

0.3%



779


817

-4.7%

-2.2%

-2.5%

WW


427


470

-9.1%

-9.2%

0.1%



1,327


1,448

-8.4%

-7.0%

-1.4%

DIAGNOSTICS
















US


-


-

-

-

-



-


-

-

-

-

Intl


7


16

-56.3%

-55.8%

-0.5%



66


62

6.5%

21.1%

-14.6%

WW


7


16

-56.3%

-55.8%

-0.5%



66


62

6.5%

21.1%

-14.6%

ORTHOPAEDICS
















US 


1,343


1,312

2.4%

2.4%

-



4,099


3,942

4.0%

4.0%

-

Intl


908


869

4.5%

4.5%

0.0%



2,848


2,897

-1.7%

0.9%

-2.6%

WW


2,251


2,181

3.2%

3.2%

0.0%



6,947


6,839

1.6%

2.7%

-1.1%

HIPS
















US


190


185

2.7%

2.7%

-



590


568

3.9%

3.9%

-

Intl


130


124

4.8%

6.4%

-1.6%



421


410

2.7%

6.5%

-3.8%

WW


320


309

3.6%

4.2%

-0.6%



1,011


978

3.4%

5.0%

-1.6%

KNEES
















US


223


214

4.2%

4.2%

-



696


662

5.1%

5.1%

-

Intl


132


129

2.3%

4.0%

-1.7%



433


429

0.9%

4.3%

-3.4%

WW


355


343

3.5%

4.1%

-0.6%



1,129


1,091

3.5%

4.8%

-1.3%

TRAUMA
















US


389


368

5.7%

5.7%

-



1,151


1,083

6.3%

6.3%

-

Intl


248


239

3.8%

3.1%

0.7%



764


801

-4.6%

-2.1%

-2.5%

WW


637


607

4.9%

4.6%

0.3%



1,915


1,884

1.6%

2.7%

-1.1%

SPINE & OTHER
















US


541


545

-0.7%

-0.7%

-



1,662


1,629

2.0%

2.0%

-

Intl


398


377

5.6%

5.0%

0.6%



1,230


1,257

-2.1%

0.0%

-2.1%

WW


939


922

1.8%

1.6%

0.2%



2,892


2,886

0.2%

1.1%

-0.9%

SURGERY
















US


1,002


987

1.5%

1.5%

-



3,003


2,947

1.9%

1.9%

-

Intl


1,282


1,233

4.0%

3.9%

0.1%



3,906


3,857

1.3%

4.3%

-3.0%

WW


2,284


2,220

2.9%

2.9%

0.0%



6,909


6,804

1.5%

3.2%

-1.7%

ADVANCED
















US


390


357

9.2%

9.2%

-



1,131


1,046

8.1%

8.1%

-

Intl


494


438

12.8%

13.0%

-0.2%



1,478


1,359

8.8%

11.9%

-3.1%

WW


884


795

11.2%

11.3%

-0.1%



2,609


2,405

8.5%

10.3%

-1.8%

GENERAL
















US


414


427

-3.0%

-3.0%

-



1,254


1,272

-1.4%

-1.4%

-

Intl


649


656

-1.1%

-1.1%

0.0%



2,006


2,063

-2.8%

0.0%

-2.8%

WW


1,063


1,083

-1.8%

-1.8%

0.0%



3,260


3,335

-2.2%

-0.5%

-1.7%

SPECIALTY
















US


198


203

-2.5%

-2.5%

-



618


629

-1.7%

-1.7%

-

Intl


139


139

0.0%

-1.2%

1.2%



422


435

-3.0%

0.3%

-3.3%

WW


337


342

-1.5%

-2.0%

0.5%



1,040


1,064

-2.3%

-1.0%

-1.3%

VISION CARE
















US


277


262

5.7%

5.7%

-



767


758

1.2%

1.2%

-

Intl


462


421

9.7%

5.3%

4.4%



1,297


1,202

7.9%

7.7%

0.2%

WW


739


683

8.2%

5.5%

2.7%



2,064


1,960

5.3%

5.2%

0.1%

















TOTAL MEDICAL DEVICES
















US


3,048


3,005

1.4%

1.4%

-



9,118


8,980

1.5%

1.5%

-

Intl


3,111


3,089

0.7%

-0.2%

0.9%



9,559


9,730

-1.8%

0.5%

-2.3%

WW


$      6,159


6,094

1.1%

0.7%

0.4%



$      18,677


18,710

-0.2%

1.0%

-1.2%

















































































































* Percentage greater than 100%








** Not meaningful








(1) Operational growth excludes the effect of translational currency








(2) Unaudited








(3) Reported as U.S. sales








(4) Prior year amounts have been reclassified to conform to current year product disclosure








 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2016-third-quarter-results-300346521.html

SOURCE Johnson & Johnson